Marks WH, et al. - Researchers summarized the results of a phase 2, randomized, multicenter, open-label, two-arm study that examined eculizumab regarding its safety and efficacy in preventing acute antibody-mediated rejection (AMR) in sensitized recipients of living-donor kidney transplants requiring pretransplantation desensitization (NCT01399593). Desensitization was done in 102 patients. Fifty-one patients received standard of care (SOC) and 51 received eculizumab posttransplantation. The patients well-tolerated eculizumab with no new safety concerns. Eculizumab (9.8%) and SOC (13.7%) led to no significant difference in treatment failure rate. Findings suggest that compared with SOC, eculizumab could provide a potential benefit in preventing acute AMR in recipients sensitized to their living-donor kidney transplants.